Survivin Vaccine: Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)

Inclusion Criteria

• Patients with histologically confirmed multiple myeloma that are being considered for high dose chemotherapy and autologous stem cell transplant
• Patients must have a bone marrow biopsy available, or one scheduled to be performed for a clinical indication so that survivin expression could be determined (note: survivin staining in tumor need not be resulted prior to enrollment or treatment as it is obtained for correlative science)
• Patients are planned for treatment with high dose melphalan and autologous hematopoietic cell transplantation (HCT)
• Absolute neutrophil count (ANC) >= 1,000/uL
• Hemoglobin >= 8.0 g/dL
• Platelet count >= 50,000/uL
• Total bilirubin less than or equal to 2 mg/dL (> 2 mg/dL permitted if the patient has evidence of Gilbert’s disease based upon prior bilirubin elevation or genetic testing)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 1.5 X the upper limit of normal
• Signed informed consent form in accordance with institutional and federal law policies

Exclusion Criteria

• Patients with complete response (CR) or stringent CR after induction therapy as defined by International Response Criteria after most recent therapy
• Patients with progressive disease at time of transplant
• Pregnant or lactating woman (as evaluated by serum testing within 48 hours of administration of the first vaccine in women of child bearing potential)
• Human immunodeficiency virus (HIV) infection confirmed by nucleic acid testing (NAT)
• Common variable immunodeficiency
• Active central nervous system (CNS) malignancy
• Active bacterial, fungal or viral infection
• Prior history of allogeneic hematopoietic cell transplantation
• Prior malignancy within 5 years of enrollment excluding non‐melanoma skin cancer or cervical carcinoma after curative resection, not requiring chemotherapy
• History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria‐toxoid containing vaccine